A3 adenosine receptor ligands: History and perspectives

Medicinal Research Reviews

Volumn 20, Issue 2, 2000, Pages 103-128

  Baraldi, Pier Giovanni ^a,d   Cacciari, Barbara ^a   Romagnoli, Romeo ^a   Merighi, Stefania ^b   Varani, Katia ^b   Borea, Pier Andrea ^b   Spalluto, Giampiero ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b Dipto Med Clin Sperim Sezione F   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d Dipto di Scienze Farmaceutiche   (Italy)

Author keywords

A3 receptors; Adenosine; Affinity; Agonists; Antagonists; Selectivity

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 1,4 DIHYDROPYRIDINE DERIVATIVE; 5,9 DIHYDRO 6 METHOXYCARBONYL 9 METHYL 2 PHENYL 1,2,4 TRIAZOLO[5,1 A][2,7]NAPHTHYRIDINE; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; BW A1433U; FLAVONOID; GALANGIN; GUANINE NUCLEOTIDE BINDING PROTEIN; L 268605; MRS 1042; MRS 1067; MRS 1088; MRS 1097; MRS 1177; MRS 1186; MRS 1334; NIFEDIPINE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PYRIDINE DERIVATIVE; TRIAZOLOQUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VUF 8501; VUF 8504; VUF 8505; VUF 8507; XANTHENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HEART PROTECTION; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; RECEPTOR AFFINITY; REVIEW; SMOOTH MUSCLE RELAXATION;

ANIMALS; HUMANS; LIGANDS; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1;

EID: 0034052190     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(200003)20:2<103::AID-MED1>3.0.CO;2-X     Document Type: Review

References (92)

1. Burnstock O. In: Bolis L, Straub RW, editors. Cell membrane receptors for drugs and hormones: a multi-disciplinary approach. New York: Raven; 1978. p 107.
2. Tucker AL, Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 1993;27:62-67.
3. 3 adenosine receptor. Proc Natl Acad Sci USA 1992;89:7432-7436.
4. Meyerhof W, Müller-Brechlin R, Richter D. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 1991;284:155-160.
5. 3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 1993;44:524-532.
6. 3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-10369.
7. 3 adenosine receptor. Biochim Biophys Acta Mol Cell Res 1993;1179;105-107.
8. 3 receptors. J Pharmacol Exp Ther 1997;280:122-128.
9. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994;15:298-306.
10. 3-adenosine receptors. Drug Dev Res 1994;33:51-59.
11. 3) to human chromosome 1p. Genomics 1995;26:637-638.
12. 3 adenosine receptor variant. FEBS Lett 1996;382:125-129.
13. 2 receptors. Trends Pharmacol Sci 1991;12:326-328.
14. O'Dowd BF, Hnatowich M, Regan JW, Leader WM, Caron MG, Lefkowitz RJ. Site-directed mutagenesis of the cytoplamic domains of the human beta 2-adrenergic receptor. Localization of regions involved in G protein-receptor coupling. J Biol Chem 1988;263:15985-15992.
15. O'Dowd BF, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M. Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem 1989;264:7564-7569.
16. 3 adenosine receptor. J Biol Chem 1995;270:16895-16902.
17. Ali H, Cunha-Melo JR, Saul WF, Beaven MA. Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. J Biol Chem 1990;265:745-753.
18. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-16890.
19. 3 receptors in rat brain. Mol Pharmacol 1995;48:1038-1045.
20. 2+ ionophore-induced secretion in a rat mast cell line. J Pharmacol Exp Ther 1996;276:837-845.
21. 3 receptor agonists. Biochem Biophys Res Comm 1996;219:904-910.
22. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 1996;88:3569-3574.
23. 3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells. Am J Physiol 1999;276:C659-C666.
24. 3 adenosine receptor: evidence for a G-protein-coupled receptor kinase-mediated mechanism. J Bio Chem 1995;270:29607-29613.
25. Lohse M. Mechanism of membrane receptor desensitization. Biochim Biophys Acta 1993;1179:171-189.
26. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-1061.
27. 3 adenosine receptor. Mol Pharmacol 1994;45:978-982.
28. 3 adenosine receptor. Mol Pharmacol 1994;45:1101-1111.
29. 125I]AB-MECA) labels multiple adenosine receptor subtypes in rat brain. Brain Res 1997;745:10-20.
30. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future 1995;20:689-699.
31. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19:184-191.
32. 3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 1994;263:59-67.
33. 3 receptor stimulation on seizures in mice. Eur J Pharmacol 1995;275:23-29.
34. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol 1999;367:157-163.
35. 3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann New York Acad Sci 1997;241:297-304.
36. 3 receptors potentiate hippocampal calcium current by a PKA-dependent/PKC-independent pathway. Neuropharmacol 1997;36:353-362.
37. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation 1986;74:1124-1136.
38. 3 adenosine receptors with N -(3-Iodobenzyl)adenosine-5′-N-Methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80:800-809.
39. 3 receptors in protection of isolated human atrial muscle against stimulated ischaemia. Cardiovasc Res 1997;36:52-59.
40. 3 receptor: sustained cardioprotection. Proc Natl Acad Sci USA 1998;95:6995-6999.
41. 3 receptor-mediated hypotensive response in the rat. Eur J Pharinacol 250;185-188.
42. 3 antagonists. Biochem Biophys Res Comm 1997;232:317-322.
43. 3 adenosine receptors. J Immunol 1996;156:3435-3442.
44. Szabó C, Scott GS, Virág L, Egnaczyk G, Salzman AL, Shanley TP, Haskó G. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-387.
45. 3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998;358:261-268.
46. 3-receptors by in-situ hybridization in human lung. Drug Dev Res 1994;31:Abstr 1307.
47. 6-2-(4-aminophenyl)ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. J Pharmacol Exp Ther 1996;279:1148-1156.
48. 3 receptors on human eosinophils mediate inhibition of degranulation and superoxide release. Br J Pharmacol 1999;127:188-194.
49. 3-selective adenosine agonists. J Med Chem 1994;37:636-646.
50. 3 adenosine receptors. J Med Chem 1994;37:3164-3621.
51. 3 adenosine receptor agonists. Bioorg Med Chem 1995;3:1331-1343.
52. Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist III JA, Schneller SW, Cristalli G, Stiles GL, Johnson CR, IJzerman AP. Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonist at adenosine receptors. J Med Chem 1995;38:1174-1188.
53. 3 adenosine receptors. J Med Chem 1995;38:1720-1735.
54. 3 adenosine receptors. J Med Chem 1996;39:802-806.
55. 3 adenosine receptor agonists. J Med Chem 1998;41:3174-3185.
56. 3 adenosine receptor agonists: an overview. Exp Opin Ther Patents 1999;9:515-527.
57. 3 selective ligands containing bioisosteric isoxazoles. Bioorg Med Chem Lett 1998;8:1767-1770.
58. 3 ligands controlling cytokines. Drug Dev Res 1996;37:173.
59. Knutsen LJS, Olsen UB, Bowler AN. A method of treating disorders related to cytokines in mammals. WO 1997;33591-A1.
60. Jacobson KA, Suzuki F. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. Drug Dev Res 1996;39:289-300.
61. de Zwart M, Kourounakis A, Kooijman H, Spek AL, Link R, von Frijtag Drabbe Kunzel JK, IJzerman AP. 5′-N-substituted carboxamidoadenosine as agonists for adenosine receptors. J Med Chem 1999;42:1384-1392.
62. 3 receptors. J Med Chem 1999;42:1393-1400.
63. 3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem 1994;37:4020-4030.
64. 3 adenosine receptors. J Med Chem 1994;37:3373-3382.
65. Olah ME, Jacobson KA, Stiles GL. Role of the second extracellular loop of adenosine receptor in agonist and antagonist binding. J Bio Chem 1994;269:24692-24698.
66. 2 adenosine receptors. J Med Chem 1986;29:1683-1689.
67. Ji XD, Melman N, Jacobson KA. Interaction of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 1996;39:781-788.
68. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Ann Rev Pharmacol Toxicol 1995;35:581-606.
69. Karton Y, Jiang JL, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA. J Med Chem 1996;39:2293-2301.
70. Moro S, van Rhee AM, Sanders LH, Jacobson KA. Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J Med Chem 1998;41:46-52.
71. Triggle DJ. Drugs acting on ion channels and membranes. In: Emmett JC, editor. Comprehensive medicinal chemistry. Vol. 3. London: Pergamon; 1985; p 1047-1099.
72. Hu PS, Lindgren E, Jacobson KA, Fredholm BB. Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors. Pharmacol Toxicol 1987;61:121-125.
73. Ismail NA, Shaheen AA, El-Sawalhi MM, Megahed YM. Effect of calcium channel antagonists in modifying the inhibitory influence of adenosine on insulin secretion. Arzneim Forsch/Drug Res 1995;45:865-868.
74. 3 receptors. J Med Chem 1996;39:2980-2989.
75. 2+ Antagonist receptor sites on human red blood cell membranes. Eur J Pharmacol 1985;108:329-330.
76. 3H]nitrobenzylthioinosine binding to the adenosine transporter in human brain. Eur J Pharmacol 1993;238:131-138.
77. 3 adenosine receptor antagonists. J Med Chem 1996;39:4667-4675.
78. 3 adenosine receptor antagonists. J Med Chem 1997;40:2596-2608.
79. 3 adenosine receptor antagonists. J Med Chem 1998;41:3186-3201.
80. 3 adenosine receptor antagonists. J Med Chem 1999;42:706-721.
81. 3 adenosine antagonists: structural homology and receptor docking. J Chem Inf Comp Sci 1998;38:1239-1248.
82. 3 receptor subtype. J Med Chem 1996;39:4142-4148.
83. 3 receptor subtypes. J Med Chem 1998;41:2835-2845.
84. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem 1998;41:3987-3993.
85. 3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. J Med Chem 1998;41:3994-4000.
86. 3 adenosine receptor antagonists. Drug Dev Res 1996;37:131.
87. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 1998;6:523-533.
88. 3 adenosine receptor antagonists. J Med Chem 1999;42:4473-4478.
89. 2A adenosine antagonists. J Med Chem 1996;39:1164-1171.
90. 2A adenosine receptor antagonists. J Med Chem 1998;41:2126-2133.
91. 3 adenosine receptor agonist. Exp Cell Res 1998;243:383-397.
92. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 1998;357:1-9.